Related Experiment Video
Updated: Dec 20, 2025
Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
Published on: June 28, 2018
Allogenic mouse cell vaccine inhibits lung cancer progression by inhibiting angiogenesis
Jun Zhao1,2, Xiaoling Zhang1, Yunyi Du1
1Department of Oncology, Changzhi People's Hospital , Changzhi, China.
Abstract:
Aim: This research investigated the therapeutic effect of an allogeneic mouse brain microvascular endothelial cell vaccine on lung cancer and further elucidated its potential anti-angiogenic mechanism. Materials & methods: The immune effect of the allogeneic bEnd.3 vaccine and DC vaccine loaded with bEnd.3 antigen on the subcutaneous transplantation of Lewis lung cancer (LLC) was assessed by ELISA, the CCK test and the CTL killing test. The mechanism was preliminarily revealed by immunohistochemistry and immunoblot analysis. Results: This study revealed that tumor volume was decreased (p < .01) and the survival was prolonged significantly (p < .05) by the bEnd.3 vaccine in subcutaneous LLC transplantation in the vaccine prevention group. In contrast, both tumor volume in the serum therapeutic group and survival of bEnd.3 vaccine were not significantly different from those of the control group (p > .05). Importantly, tumor volume and survival of the T lymphocyte therapeutic group were decreased and prolonged (p < .05). In addition, both tumor volume and survival of DC vaccine loaded with bEnd.3 in the vaccine prevention group were decreased and prolonged significantly (p < .01). Furthermore, bEnd.3 vaccine and DC vaccine loaded with bEnd.3 both produced the activity of killing bEnd.3 target cells in vitro.The reason may induce the immune mice to produce anti-VEGFR-II, anti-endoglin and anti-integrin αν antibodies to have an anti-angiogenesis function. Conclusion: The allogeneic mouse bEnd.3 cell vaccine can block angiogenesis and prevent the development of lung cancer transplantation tumors.
Insights
An allogeneic mouse brain microvascular endothelial cell vaccine effectively reduced lung cancer tumor volume and prolonged survival by blocking angiogenesis. This immunotherapy shows promise for preventing lung cancer development.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Biology
Background:
- Lung cancer remains a leading cause of cancer-related mortality worldwide.
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
- Developing novel therapeutic strategies targeting tumor angiogenesis is essential.
Purpose of the Study:
- To investigate the therapeutic effect of an allogeneic mouse brain microvascular endothelial cell (bEnd.3) vaccine on lung cancer.
- To elucidate the anti-angiogenic mechanism of the bEnd.3 vaccine.
- To evaluate the efficacy of the bEnd.3 vaccine and a dendritic cell (DC) vaccine loaded with bEnd.3 antigen in preventing and treating lung cancer.
Main Methods:
- Subcutaneous transplantation of Lewis lung cancer (LLC) in mice.
- Assessment of immune effects using ELISA, CCK test, and CTL killing assay.
- Immunohistochemistry and immunoblot analysis to reveal the anti-angiogenic mechanism.
Main Results:
- The bEnd.3 vaccine significantly decreased tumor volume and prolonged survival in the vaccine prevention group.
- The DC vaccine loaded with bEnd.3 antigen also significantly reduced tumor volume and extended survival.
- Both vaccines demonstrated in vitro activity against bEnd.3 target cells, suggesting an anti-angiogenic function possibly through antibodies against VEGFR-II, endoglin, and integrin αν.
Conclusions:
- The allogeneic mouse bEnd.3 cell vaccine effectively blocks angiogenesis.
- This vaccine demonstrates potential in preventing the development of lung cancer transplantation tumors.
- The findings support the development of bEnd.3 cell-based vaccines as a novel immunotherapy for lung cancer.
